Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisinin-based combination therapy with curcumin is an investigational approach for malaria treatment. Artesunate, a derivative of artemisinin, acts as a potent antimalarial by generating free radicals that damage the parasite's membranes and proteins. Curcumin, the active component of turmeric, has demonstrated antiplasmodial activity and may protect against oxidative stress induced by artesunate. When combined in polymeric nanoparticles (e.g., PLGA), these drugs show improved bioavailability and enhanced antimalarial efficacy compared to monotherapy or free drug forms[1][2]. The combination has been shown to increase parasite suppression rates by 10–30% over individual agents in preclinical models[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artesunate + curcumin.